Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study

Boris Schnorbus,1,2 Andreas Daiber,1 Kerstin Jurk,2 Silke Warnke,3 Jochem König,4 Ulrike Krahn,4 Karl Lackner,5 Thomas Munzel,1 Tommaso Gori1

ABSTRACT

Introduction: Particularly in the setting of acute coronary syndromes, the interplay between vascular and platelet function has been postulated to have direct clinical implications. The present trial is designed to test the effect of clopidogrel, prasugrel and ticagrelor on multiple parameters of vascular function, platelet aggregation, oxidative and inflammatory stress before and up to 4 weeks after coronary artery stenting.

Methods and analysis: The study is designed as a three-arm, parallel design, randomised, investigator-blinded study. Patients with unstable angina or non-ST elevation myocardial infarction undergoing coronary intervention with a drug-eluting stent will be randomised to receive 600 mg clopidogrel, 60 mg prasugrel or 180 mg ticagrelor followed by oral therapy with the same drug. The primary endpoint of the trial is the impact of antiplatelet treatments on endothelial function as assessed by flow-mediated dilation at 1 day, 1 week and 1 month in patients who have undergone stenting. Secondary endpoints include the impact of study medications on parameters of macrovascular and microvascular function, platelet reactivity, oxidative and inflammatory stress. The study recruitment is currently ongoing and, after an interim analysis which was performed at 50% of the initially planned population, it is planned to continue until July 2015.

Ethics and dissemination: The protocol was approved by the local ethics committee. The trial will provide important pathophysiological insight on the relationship between platelet aggregation and endothelial function, two parameters that have been shown to influence patients’ prognosis.

Trial registration number: ClinicalTrials.gov Identifier: NCT01700322; EudraCT-Nr.: 2011-005305-73. Current V.1.3, from 24 February 2014.

Strengths and limitations of this study

▪ This is the first study comparing all three antiaggregants currently used in a controlled, investigator-blinded randomised way. The study is funded by a public institution without involvement of the industry. The study enrolls a population at particular risk (unstable coronary syndromes) and provides clinically relevant information. The study has an own biometrician, uses professionally prepared medications, is sponsored by an external public-funded institution, is monitored and managed by a professional contract research organisation.

▪ The study uses a number of surrogate endpoints and is not powered for mortality or other clinical events. There is no double-blind, double dummy approach (this was not allowed due to the size of the ticagrelor tablets, which cannot be neither inserted in capsules nor reduced to powder).

BACKGROUND

A number of studies show that coronary artery stenting is associated with an immune/inflammatory response.1–7 Importantly, such changes have been identified as a possible cause of in-stent restenosis and in-stent thrombosis, which, despite being relatively rare, are the two major complications that may follow implantation of coronary stents. To date, the pathophysiological link between inflammation, platelet reactivity and stent thrombosis/restenosis remains unclear, although it is believed that endothelial dysfunction and/or platelet activation...
induced by inflammation play a central role. In line with this hypothesis, previous studies have shown that stenting is associated with impaired coronary and peripheral endothelial responsiveness, and that the degree of endothelial dysfunction early after stenting can be used as a predictor for long-term outcome. In this scenario, the role of platelets remains less well investigated. We recently demonstrated that, when given acutely, antiplatelet agents improve endothelial function. However, the beneficial effects of clopidogrel are lost upon prolonged treatment, and, acutely, clopidogrel does not prevent stent-induced vascular dysfunction. Further, another issue with clopidogrel is the well-known individual resistance to the antiplatelet effects of this drug. In order to address this issue, alternatively, more potent antiplatelets drugs such as prasugrel and ticagrelor with more predictable efficacy have been introduced. The impact of these more modern antiaggregants on endothelial function is unknown and no study to date has compared the three antiaggregant drugs in a randomised, blinded fashion.

HYPOTHESIS OF THE STUDY
We set out to study the acute and chronic effects of clopidogrel, prasugrel and ticagrelor on parameters of vascular and thrombocyte function in patients with acute coronary syndromes undergoing coronary stenting. We hypothesise that the more potent antiaggregants will prevent endothelial dysfunction, as well as the oxidative and inflammatory stress induced by stenting.

METHODS AND ANALYSIS
Primary objective: The primary objective of the trial was to investigate the impact of the three treatments under study on endothelial function (as assessed by flow-mediated dilation, FMD) in patients with acute coronary syndromes undergoing coronary stenting. We hypothesise that the more potent antiaggregants will prevent endothelial dysfunction, as well as the oxidative and inflammatory stress induced by stenting.

Secondary objectives include the following:
- To test the impact of study medications on several parameters of conduit and resistance artery function after acute loading and chronic dosing of the three study drugs.
- To investigate the changes in markers of platelet function, inflammatory and oxidative stress.
- To compare two different methods to assess platelet function.
- To investigate the safety and tolerability of clopidogrel, prasugrel and ticagrelor.

STUDY DESIGN
This is a prospective, single-centre, investigator-blinded, randomised, parallel group design trial conducted at the Center of Thrombosis and Hemostasis of the University Center Mainz, Germany in collaboration with the Department of Medicine II, the Institute for Clinical Chemistry and Laboratory Medicine, the Institute of Medical Biostatistics, Epidemiology and Informatics, the Pharmacy and the Interdisciplinary Center for Clinical Studies. The recruitment of the first patient started in October 2013. The duration of this study is expected to be 24 months.

SELECTION OF PARTICIPANTS
Recruitment
Patients will be enrolled by the investigators among those undergoing coronary stenting in the Department of Medicine II at the University Medical Center Mainz. Patients should be haemodynamically stable and should have chest pain with characteristics suggestive of an unstable presentation (eg, recent onset, crescendo angina, with episodes at rest or minimal exercise, decreasing effect of short acting nitrates) with or without elevated markers of myocardial necrosis. The main inclusion and exclusion criteria are listed in box 1. The Principal Investigator or a delegate will describe all study procedures and all patients will provide written informed consent. Patients who undergo screening and the initial study procedures, but who will not undergo stent implantation (eg, due to the absence of coronary artery stenoses, or to a coronary artery disease with indication to surgery) will be considered dropouts and will not continue the study.

Randomisation and blinding
Participants will be randomised if all inclusion criteria are met and no exclusion criterion is met. Randomisation will be carried out in a 1:1:1 ratio to prasugrel, ticagrelor or clopidogrel using block randomisation without stratification by means of an SAS program. On the basis of the randomisation list, study drugs will be prepared and packaged in identical packages by the pharmacy of the University Medical Centre Mainz. Individual sealed envelopes will be opened at the time of randomisation by a study nurse not involved in other study procedures, who will also administer the drugs and check compliance by counting of tablets at follow-up visits. All other study personnel will remain blinded to the allocation group. Participants will be instructed to bring all trial medication to the trial site at every visit. Additional sealed envelopes will remain in custody of the study centre, and will remain sealed if not in medical emergencies (in this case, the date and the reasons for doing so will be recorded in the electronic case report form (eCRF), in the participant's medical record and on the randomisation envelope; whenever possible, the PI will be contacted before the blind is broken).

Trial schedule
The trial schedule is presented in figure 1 and table 1. Participants will undergo seven visits (6 for those enrolled after amendment 1). Vascular function, platelet
Inclusion and exclusion criteria

**Box 1** Inclusion and exclusion criteria

**Inclusion criteria**
- 18–75-year-old consecutive patients undergoing coronary angiography and stenting at the University Medical Centre Mainz.
- A coronary lesion (and patient) amenable to treatment with drug eluting stent.
- Ability of participant to understand character and individual consequences of clinical trial.
- Signed and dated informed consent of the participant must be available before start of any specific trial procedures.
- Women with childbearing potential have to be practicing a medically accepted contraception until the completion of the trial or signing of informed consent.

**Exclusion criteria**
- Patients with elevated (>5 times upper normal limit) C reactive protein level prior to stenting.
- Patients in whom therapy with long-acting nitrates cannot be suspended prior to endothelial function measurements.
- An acute coronary syndrome treated with coronary stenting within the last 4 weeks.
- Patients with known inflammatory/infective diseases.
- Patients with severe extracardiac diseases limiting life expectancy.
- Known heart failure (left ventricular ejection fraction ≤40% and New York Heart Association III–IV).
- Percutaneous coronary intervention or coronary by-pass surgery within the last 4 weeks, pre-existing ongoing treatment with any of the study treatments.
- History of cerebrovascular events (stroke).
- Known renal dysfunction (serum creatinine ≥1.8 mg/dL in women, ≥2.0 mg/dL in men).
- Serum potassium >5.5 mmol/L.
- Known hepatic impairment (aspartate aminotransferase, alanine aminotransferase >3 times upper limit of normal).
- Changes in the β-blocker or ACE-inhibitor or angiotensin-receptor blocker treatment within the past 2 weeks.
- Pregnancy and lactation, inadequate contraception.
- Body weight <60 kg.
- Active bleeding.
- Therapy with CYP3A4 inhibitors (ketoconazole, protease inhibitors, macrolide antibiotics).
- Therapy with anticoagulants: phenprocoumone, warfarin, dabigatran, rivaroxaban.
- History of hypersensitivity to any of the investigational medicinal products or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.
- Ongoing participation in other clinical trials or within the last 3 months, or ongoing therapy with one of the study medications.
- Medical or psychological condition that would not permit completion of the trial or signing of informed consent.
- Patients with acute ST-elevation myocardial infarction.

Function and markers of oxidative/inflammatory stress will be measured at screening, 2 h after the loading dose (only for patients recruited before amendment 1), and 1 day, 1 week, 1 month after stenting. The trial schedule was amended on 24 February 2014 following the November 2013 warning by the European Medicines Agency (EMA/90532/2014) recommending the administration of prasugrel only at the time of coronary intervention. In consequence, the 2-h visit was eliminated from the protocol. At the end of recruitment, 50% of the participants will have been enrolled according to the original protocol and 50% according to amendment 1, which will also allow to test whether the timing of the administration has an impact on the endpoints under study.

**Study intervention**

The treatments under study include:
- Clopidogrel
- Prasugrel
- Ticagrelor

All drugs are administered orally as a single loading dose of 600 mg (clopidogrel), 60 mg (prasugrel) or 180 mg (ticagrelor) followed by chronic treatment. Ticagrelor is administered orally in a dosage of 90 mg twice daily. Prasugrel is administered orally in a dosage of 10 mg once daily and clopidogrel is administered orally in a dosage of 75 mg once daily. Treatment will be protracted for at least 1 year after stenting (table 2).

**Concomitant medication**

If not already administered prior to admission to the hospital, patients will receive treatment with aspirin 500 mg intravenously before the first endothelial function measurements are performed. Procedures in the catheterisation laboratory including choice of catheters, coronary wires and balloons and use of intravascular ultrasound will be left to the operator’s choice. As per inclusion criteria, all patients will receive at least one drug eluting stent. On discharge, all patients will receive treatment with simvastatin at least 20 mg once daily and acetylsalicylic acid 100 mg once daily.

**Analytical methods**

**Assessment of endothelial function**

The methods used in our laboratory to assess FMD and flow-mediated constriction (L-FMC) have been recently described.21–25 The analysis of endothelial function data will be performed offline by personnel blinded to the allocation group (also in the case of withdrawal of the patient from the study and/or from the study medication; figure 2).

**Assessment of microvascular function**

Reactive hyperaemia and autonomic outflow to the peripheral microvasculature will be assessed using laser Doppler flowmetry (Perimed, Sweden). This device
measures microvascular blood flow by measuring changes in the frequency of a laser beam reflected from red blood cells. Parameters assessed include microvascular reactive hyperaemia as well as the sympathetic, myogenic and endothelial components of microvascular tone. Methods are described in refs.26–28

Laboratory analyses
At screening, blood will be sampled for the assessment of cardiac markers and blood counts and other parameters as clinically indicated (eg, liver enzymes, creatinine, total cholesterol, high-density and low-density lipoprotein cholesterol) in the central laboratory using standard techniques. Platelet reactivity will be assessed by aggregation testing by using Multiplate and light transmission aggregometry in response to adenosine diphosphate. At all visits an additional blood sample of plasma and serum will be stored at −80°C after centrifugation until analysis for determination markers of inflammation and oxidative stress by ELISA. Markers will include, but not be limited to, osteoprotegerin, endothelin-1, monocyte chemotactic protein-1, chemokine ligand 5, E selectin, interleukin-6, CD-40, high-sensitivity C reactive protein. Additionally, plasma will be stored for biobanking. Finally, leucocyte oxidative burst will be assessed in fresh blood.29

Statistics
Details of the statistical analysis of the data collected in this trial will be documented in a Statistical Analysis Plan (SAP) generated by the trial statistician and finalised before closing the database and prior to breaking the blind. The SAP is based on the protocol including all amendments. The statistical analysis will be conducted by means of SAS or SPSS.

Sample size
For comparison of the three treatment arms with respect to the average FMD over the three measurements after stenting, we will use an ordered test strategy.30 First, prasugrel and ticagrelor will be tested separately versus clopidogrel by a one-sided t test for independent samples at a nominal level of 0.0125. This assures a multiple significance level of 0.025 by virtue of the Bonferroni correction method. If at least one of the two null hypotheses is rejected, the two treatments prasugrel and ticagrelor will be tested for difference by a two-sided t test at a significance level of 0.05. The preceding testing (prasugrel and ticagrelor separately vs clopidogrel) has in each case an adaptive design with an interim analysis. The weighted inverse normal combination method and an O’Brien-Fleming-design will be used with a binding stopping for futility. A planned secondary analysis will be performed separately for all
patients recruited after amendment 1, provided in the primary final analysis a statistically significant difference between some treatments according to the specified adaptive test is detected.

The initial sample size calculation (ADDPLAN 4.0) is based on a simplified analysis applied to one prespecified time point (eg, 4 weeks) with the following assumptions:
- SDs in each group=3%.
- Mean difference between groups=2.6%.
- Power of 0.90.

Based on this sample size estimation, it is calculated that a total of 150 patients will be enrolled in the trial.

An interim analysis was conducted at 50% recruitment (90 patients enrolled, 56 in-study, 34 dropout). The investigators remained blinded to its results, which were discussed within the trial’s Data Safety Board.

Primary analysis will be based on a modified intention to treat analysis set, containing all patients who received a stent and have at least one FMD measurement during follow-up.

Analysis will be based on fitting a linear mixed model to all available measurements of the primary outcome variable FMD percentage under treatment (1, 7 and 28 days).

For primary analysis, the average level of the outcome variable (over 3 points in time) will be compared between the three treatment arms.

The use of a mixed model is among the methods to cope with missing data recommended by the EMA guideline on missing data in confirmatory clinical trials. It makes effective use of all data and avoids bias by selection of patients with complete data only under the general assumption of non-informative missingness.

The use of the mixed model within the framework of adaptive testing is as follows: for stage 1 the model is fitted to the data of three treatment arms. If the study is not stopped; the model is fitted to the data of stage 2, which will contain two or three treatment arms and the

| Table 1 Trial schedule |
|------------------------|
| **Visit** | **Screening** | **Visit 1** | **Visit 2 (only patients 1–90)** | **Visit 3** | **Visit 4** | **Visit 5** | **Follow-up** |
| Trial day | 1 | 1 (randomisation) | 1 (2 h after first dose) | 1 (6–12 h after intervention) | 2 (1 day after intervention) | 7 (±2) | 28 (±3) |
| Demographics (eg, sex, age, ethnicity) | X | | | | | | |
| Patient information and informed consent | X | | | | | |
| Previous and concomitant diseases | X | | | | | | |
| Previous and concomitant treatments | X | | | | | | |
| Inclusion/exclusion criteria | X | | | | | |
| Physical examination | X | | | | | |
| Vital signs (BP, pulse, temperature) | X | X | X | X | X | | |
| Lab I (CK, troponin I, renal function) | X | | | | | |
| Lab II (oxidative stress, inflammatory, platelet function) | X | X | X | X | X | X | X |
| FMD | X | | X | X | | X | X |
| L-FMC | X | | X | X | | X | X |
| Reactive hyperaemia | X | | X | X | | X | X |
| Randomisation | X | | | | | | |
| Adverse events | X | X | X | X | X | | |
| End of trial (final visit) | | X | | X | X | | |

BP, blood pressure; FMD, flow-mediated dilation; FMC, flow-mediated constriction.

| Table 2 Dosage schedule |
|-------------------------|
| **Drug** | **Loading dose (mg)** | **Chronic treatment** | **Morning** | **Evening** |
| Clopidogrel | 600 | 75 | | |
| Prasugrel | 60 | 10 | | |
| Ticagrelor | 180 | 90 | 90 | |

Schnorbus B, Daiber A, Jurk K, et al. BMJ Open 2014;4:e005268. doi:10.1136/bmjopen-2014-005268
p values for one or both primary comparisons will be combined according to the inverse normal method. If one of the two primary comparisons (prasugrel vs clopidogrel and ticagrelor vs clopidogrel) is significant, the direct comparison between prasugrel and ticagrelor will be based on a model fit to all data available at completion of the study.

The multiple type I error is controlled by the procedure described in the preceding paragraph.

Effects on secondary outcomes and on the FMD for each time point will be estimated within the same fitted model with unadjusted 95% CIs.

Legal considerations
Analysis of adverse events will be conducted according to good clinical practice, the ethical principles described in the Declaration of Helsinki, the local legal and regulatory requirements and those of the European Medicines Agency and the Federal Data Protection Law of Germany. Patients are insured against any harm resulting from trial participation.

Audit
Competent authorities and sponsor authorised persons (auditor) may request access to all source documents, CRF and other trial documentation in case of an inspection or audit. Direct access to these documents must be guaranteed by the investigator who must provide support at all times for these activities. Source data documents can be copied during inspection or audit in case the identity of the participant have been made unrecognisable.

Confidentiality
The participants’ name and other personal information will be retained by the investigator. During the clinical trial, participants will be identified solely by individual identification codes (randomisation number). Data storage will be performed in accordance with local data protection laws. The participant will declare in the written consent form that he/she allows to release the investigator from the medical professional secrecy to permit identification of participant’s name and/or inspection of original data for monitoring purposes by health authorities and authorised persons (monitors). The investigator will maintain a personal participant identification list (participant numbers with the corresponding participant names) to enable records to be identified.

Dissemination
Publication resulting from the study shall require the approval of the external scientific advisory board of the Center for Thrombosis and Hemostasis (CTH). The results of the trial will be published as original article(s) in medical journals and/or as presentation at congresses. The principal investigator is a (co-) first author of the article and will present the data at the major congresses. The choice of the journal for the publication will be made by the principal investigator in agreement with the coauthors. Besides the Principal Investigator, a
substantial contribution to the recruitment of participants, a substantial contribution to interpretation of the data and/or substantial contribution to drafting the article or revising it qualify for authorship.

**Trial status**

Recruitment of patients is ongoing. The last patient was included in October 2012. After the interim analysis, we expect that the last patient will conclude the study procedures in July 2015.

**Author affiliations**

1. Department of Medicine II, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
2. Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
3. Interdisciplinary Center for Clinical Trials, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
4. Department of Clinical Chemistry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
5. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
6. Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
7. Infarction Research Center, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
8. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
9. Interdisciplinary Center for Clinical Trials, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
10. Department of Medicine II, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
11. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
12. Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
13. Interdisciplinary Center for Clinical Trials, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
14. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
15. Department of Clinical Chemistry, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
16. Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
17. Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
18. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
19. Interdisciplinary Center for Clinical Trials, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
20. Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
21. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
22. Department of Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
23. Institute for Medical Biometry, Epidemiology, and Informatics, Johannes Gutenberg-University Mainz, Mainz, Germany
24. Interdisciplinary Center for Clinical Trials, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

**Acknowledgements**

The authors would like to thank Hannelore Seiler, Peter Weiss, Matthias Reigh and Florian Koehler for the FMD measurements. Data Safety Board: Prof M. Kelm, Universitätsklinikum Düsseldorf, Dr WD Paar, Sanofi, Prof HH Peter, Universität Freiburg and the other members of the External Advisory Board of the Center for Thrombosis and Hemostasis, University Medical Center Mainz (http://www.cth-mainz.de/cth/struktur/esab.html).

**Contributors**

BS, AD, KJ, JK and TG prepared the first draft of the manuscript. KL and TM revised the final draft of the manuscript and critically revised it for its intellectual content. All the authors substantially contributed to the conception and the design of the study. All the authors read and approved the final manuscript.

**Funding**

This work is supported by the German Federal Ministry of Education and Research (BMBF 01EO1003). The authors are responsible for the contents of this publication. Sponsor of the study: University Medical Centre of the Johannes Gutenberg-University Mainz, represented by the executive board of the University, Dean Univ-Prof Dr U. Förstermann. The sponsor is not involved in any procedure related with the protocol nor in the dissemination of the data.

**Competing interests**

TG has received honoraria from Lilly & Daiichy-Sankyo and Research (BMBF 01EO1003). The authors are responsible for the dissemination of the data.

**Ethics approval**

The study was approved by the Ethics Committee (reference code: 837-554-11 (8096) and by the BfArM (German Agency for drugs and medical products); Ethics Committee of the Landesärztekammer, Rheinland Pfalz.

**Provenance and peer review**

Not commissioned; peer reviewed for ethical and funding approval prior to submission.

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

**REFERENCES**

1. Bonz AW, Lengenfelder B, Strotmann J, et al. Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). J Am Coll Cardiol 2002;40:662–8.

2. Goldberg A, Zinder O, Zdoryavky A, et al. Diagnostic coronary angiography induces a systemic inflammatory response in patients with stable angina. Am Heart J 2003;146:219–23.

3. Almagor M, Keren A, Banai S. Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease. Am Heart J 2003;145:248–53.

4. Aggarwal A, Blum A, Schneider DJ, et al. Soluble CD40 ligand is an early initiator of inflammation after coronary intervention. Coron Artery Dis 2004;15:471–5.

5. Aggarwal A, Schneider DJ, Sobel BE, et al. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 2003;92:924–9.

6. Aggarwal A, Schneider DJ, Terrien EF, et al. Increase in interleukin-6 in the first hour after coronary stenting: an early marker of the inflammatory response. J Thromb Thrombolysis 2003;15:25–31.

7. Aggarwal A, Schneider DJ, Terrien EF, et al. Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003;91:1346–9.

8. Park DW, Yun SC, Lee JY, et al. C-reactive protein and the risk of stent thrombosis. J Am Coll Cardiol 2003;91:1346–9.

9. Papp J, Kenyeres P, Toth K. Clinical importance of antiplatelet drugs in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Circulation 2009;120:1987–95.

10. Reinhart WH. Platelets in vascular disease. Clin Hemorheol Microcirc 2013;53:81–89.

11. Inoue T, Croce K, Morooka T, et al. Vascular inflammation and repair implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057–96.

12. Togni M, Raber L, Cocchia R, et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007;120:212–20.

13. Hofma SH, van der Giessen WJ, van Dalen BM, et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. J Am Coll Cardiol 2008;52:2189–97.

14. Obata JE, Kitta Y, Takano H, et al. Sirolimus-eluting stent implantation aggravates endothelial vasomotor dysfunction in the infarct-related coronary artery in patients with acute myocardial infarction. J Am Coll Cardiol 2007;50:1305–9.

15. Meier P, Zbinden R, Togni M, et al. Coronary collateral function long after drug-eluting stent implantation. J Am Coll Cardiol 2007;50:1693–701.

16. Jabs A, Okamoto E, Vinten-Johansen J, et al. Sequential patterns of chemokine- and chemokine receptor-synthesis following vessel wall injury in porcine coronary arteries. Atherosclerosis 2007;192:75–84.

17. Wamhofft A, Ostad MA, Velich N, et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008;198:689–95.

18. Ostad MA, Nick E, Paixao-Gatinho V, et al. Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. Clin Res Cardiol 2010;100:29–36.

19. Gori T, MS, Damaske A, Radmacher HC, et al. Endothelial function assessment: flow-mediated dilatation and constriction provide different and complementary information on the presence of coronary artery disease. Eur Heart J 2012;33:663–71.

20. Gori T, Radmacher HC, Muxel S, et al. Endothelial function and hemorheological parameters modulate coronary blood flow in patients without significant coronary artery disease. Clin Hemorheol Microcirc 2012;52:255–68.

21. Muxel S, Fasola F, Radmacher HC, et al. Endothelial functions: translating theory into clinical application. Clin Hemorheol Microcirc 2010;45:109–15.

22. Gori T, Dragoni S, Lisi M, et al. conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol 2008;51:1953–8.
25. Gori T, Grotti S, Dragoni S, et al. Assessment of vascular function: flow-mediated constriction complements the information of flow-mediated dilatation. *Heart* 2010;96:141–7.

26. Rossi M, Matteucci E, Pesce M, et al. Peripheral microvascular dysfunction as an independent predictor of atherosclerotic damage in type 1 diabetes patients: a preliminary study. *Clin Hemorheol Microcirc* 2013;54:381–91.

27. Gori T, Di Stolfo G, Sicuro S, et al. Correlation analysis between different parameters of conduit artery and microvascular vasodilation. *Clin Hemorheol Microcirc* 2006;35:509–15.

28. Gori T, Di Stolfo G, Sicuro S, et al. The effect of ischemia and reperfusion on microvascular function: a human in vivo comparative study with conduit arteries. *Clin Hemorheol Microcirc* 2006;35:169–73.

29. Dopheide JF, Doppler C, Scheer M, et al. Critical limb ischaemia is characterised by an increased production of whole blood reactive oxygen species and expression of TREM-1 on neutrophils. *Atherosclerosis* 2013;229:396–403.

30. Bauer P. Multistage testing with adaptive designs. *Biomed Inf Med Biol* 1989;20:130–36.